ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
121.187,91
0,34%
S&P 500
5.867,08
-0,09%
US Dollar vs BRL
6,1536
0,02%
Bitcoin
96.716,64
-0,76%
Brent Oil
72,345
-0,06%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Nuvalent Inc (NUVL)

  7. Nuvalent Inc (NUVL) Notícias

NUVL

Nuvalent (NUVL)

Nuvalent Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NUVL
DataHoraFonteTítuloCódigoCompanhia
19/12/202408:30PR Newswire (US)Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
18/12/202418:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
09/12/202408:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
09/12/202408:30PR Newswire (US)Nuvalent Appoints Grant Bogle to Board of DirectorsNASDAQ:NUVLNuvalent Inc
26/11/202408:52PR Newswire (US)Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
25/11/202418:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NUVLNuvalent Inc
12/11/202408:42Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NUVLNuvalent Inc
12/11/202408:30PR Newswire (US)Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
08/11/202416:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:NUVLNuvalent Inc
18/09/202417:05PR Newswire (US)Nuvalent Announces Closing of Upsized Public Offering of Common StockNASDAQ:NUVLNuvalent Inc
17/09/202417:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NUVLNuvalent Inc
17/09/202407:42IH Market NewsInvestors Anticipate Retail Sales Data and Fed Decision; Oil Prices Dip as Investors Weigh U.S. ProductionNASDAQ:NUVLNuvalent Inc
16/09/202423:23PR Newswire (US)Nuvalent Announces Pricing of Upsized Public Offering of Common StockNASDAQ:NUVLNuvalent Inc
16/09/202408:00PR Newswire (US)Nuvalent Announces Public Offering of Common StockNASDAQ:NUVLNuvalent Inc
14/09/202406:00PR Newswire (US)Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development TimelinesNASDAQ:NUVLNuvalent Inc
13/09/202410:53PR Newswire (US)Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655NASDAQ:NUVLNuvalent Inc
09/09/202407:30PR Newswire (US)Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class ProfilesNASDAQ:NUVLNuvalent Inc
29/08/202407:30PR Newswire (US)Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
08/08/202407:30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
22/07/202407:30PR Newswire (US)Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective InhibitorNASDAQ:NUVLNuvalent Inc
16/07/202407:30PR Newswire (US)Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024NASDAQ:NUVLNuvalent Inc
11/07/202417:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
11/07/202407:30PR Newswire (US)Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific OfficerNASDAQ:NUVLNuvalent Inc
29/05/202407:30PR Newswire (US)Nuvalent to Participate in the 2024 Jefferies Global Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
16/05/202417:01PR Newswire (US)Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655NASDAQ:NUVLNuvalent Inc
09/05/202407:30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
08/04/202417:30PR Newswire (US)Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
05/03/202418:52PR Newswire (US)Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
27/02/202409:00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NUVLNuvalent Inc
27/02/202408:42Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NUVLNuvalent Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NUVL

Seu Histórico Recente

BOV
FICT3
BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
AZEV4
AZEVEDO PN
BOV
IDIV
Dividend
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados